Radformation, a global pioneer in radiation oncology software solutions, has announced a strategic partnership with Icon Group, a worldwide leader in comprehensive cancer care. The aim of this collaboration is to revolutionize cancer care through innovative workflows and advanced software solutions.
Icon Group is known for its commitment to providing exceptional end-to-end cancer treatment and patient care. With a global network of cutting-edge cancer centers, research facilities, and pharmacy management services, Icon aims to bring the best care to as many people as possible, in their own communities.
Radformation, as a trailblazer in radiation oncology software, brings unique solutions to the partnership that simplify complex treatment planning and quality assurance workflows. Their software empowers clinicians to enhance treatment outcomes and improve patient experiences.
The collaboration between Radformation and Icon Group will co-develop and implement quality improvement tools that streamline processes, increase efficiency, and deliver the best possible care to more people. The partnership will begin with the implementation of Radformation’s AI-driven contouring solution, AutoContour, which accelerates pre-treatment planning. Radformation’s cloud-based platform, RadMachine, will also be utilized to streamline Machine QA, ensuring the safety and optimum performance of treatment delivery systems.
Both companies share a common vision of advancing radiation oncology workflows and improving the way cancer treatment is delivered. Radformation aims to provide user-friendly products that enhance the safety and quality of cancer treatment, while Icon Group is dedicated to delivering integrated, end-to-end seamless services for cancer patients.
The partnership between Radformation and Icon Group has the potential to transform cancer treatment and workflows globally. By leveraging their expertise and implementing innovative software solutions, this collaboration aims to improve access to care, enhance treatment efficiency, and deliver better outcomes for cancer patients worldwide.
